(IN BRIEF) GSK has signed an exclusive global licensing agreement with Empirico Inc. for EMP-012, a first-in-class siRNA candidate currently in Phase I trials for chronic obstructive pulmonary disease (COPD). EMP-012 targets a distinct inflammatory pathway, offering potential therapeutic benefit … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged biologics, Chronic obstructive pulmonary disease, COPD, drug development, EMP-012, Empirico, gene expression, genetic medicine, GSK, GSK Acquires Global Rights to Empirico’s siRNA Candidate EMP-012 for Chronic Obstructive Pulmonary Disease, GSK and Empirico Partner on First-in-Class siRNA Therapy EMP-012 to Address Unmet Needs in COPD, Healthcare Innovation, inflammation, inflammation pathway, Kaivan Khavandi, licensing agreement, oligonucleotide therapeutics, Omri Gottesman, Phase I clinical trial, precision medicine, respiratory diseases, respiratory pipeline, siRNA, type 2 inflammation
(IN BRIEF) Roche announced that its Phase III INShore trial evaluating Gazyva/Gazyvaro (obinutuzumab) in children and young adults with idiopathic nephrotic syndrome met its primary endpoint, showing superior sustained remission rates at one year compared to mycophenolate mofetil (MMF). The … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged B cell targeting, Basel, Chronic kidney disease, corticosteroids, EMA, FDA, Gazyva, Gazyva/Gazyvaro Demonstrates Superior Sustained Remission in Children and Young Adults With Idiopathic Nephrotic Syndrome, Gazyvaro, idiopathic nephrotic syndrome, immune-mediated kidney diseases, INS, INShore study, Levi Garraway, lupus nephritis, NOBILITY study, obinutuzumab, pediatric nephrology, phase III clinical trial, proteinuria, REGENCY study, renal disease, Roche, Roche Announces Positive Phase III INShore Results for Gazyva/Gazyvaro in Children and Young Adults With Idiopathic Nephrotic Syndrome, sustained remission, targeted therapy
(IN BRIEF) Novartis will present new data from 27 abstracts at the 2025 American College of Rheumatology (ACR) Convergence, featuring late-breaking Phase III results from the NEPTUNUS-1 and NEPTUNUS-2 trials of ianalumab in Sjögren’s disease, which could become the first … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged ACR 2025, allergy, Angelika Jahreis, autoimmune diseases, Basel, biologics, biomarker research, CAR-T therapy, Cosentyx, Dermatology, EXPLORE44, Fortitude, HARBOR trial, ianalumab, immunology, NEPTUNUS trials, NEPTUNUS-1, NEPTUNUS-2, Novartis, Novartis Highlights Strong Immunology Pipeline with Positive Phase III Sjögren’s Results and CAR-T Data in Lupus at ACR 2025, Phase III data, psoriatic arthritis, rapcabtagene autoleucel, rheumatology, secukinumab, Sjögren’s disease, small molecules, systemic lupus erythematosus, YTB323
(IN BRIEF) Novartis announced a definitive agreement to acquire Avidity Biosciences for USD 12 billion in cash, in a move that strengthens its neuroscience franchise and accelerates its xRNA therapeutic strategy. The acquisition brings Avidity’s late-stage programs in myotonic dystrophy … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged acquisition, Antibody Oligonucleotide Conjugates, AOCs, Avidity Biosciences, Basel, biopharma, biopharmaceutical innovation, biotechnology, clinical research, DM1, DMD, drug development, Duchenne muscular dystrophy, EXPLORE44 trial, facioscapulohumeral muscular dystrophy, FORTITUDE trial, FSHD, genetic medicine, HARBOR trial, muscle-directed therapy, myotonic dystrophy type 1, neuromuscular diseases, Novartis, Novartis Strengthens Neuroscience Franchise with Acquisition of Avidity Biosciences and Its Muscle-Directed RNA Platform, RNA delivery, RNA therapeutics, San Diego, SpinCo, Vas Narasimhan, xRNA strategy
(IN BRIEF) Evotec SE announced it has received a US$ 25 million payment from Bristol Myers Squibb, marking progress in their joint neuroscience partnership focused on neurodegenerative diseases. The milestone payment will further advance the companies’ preclinical pipeline and research … Read the full press release
Posted in Business, Germany, Healthcare, Investment, News, Pharma & Biotech, Science, Technology
Tagged biotechnology, BMS-986419, Bristol-Myers Squibb, clinical trials, Cord Dohrmann, disease-modifying therapies, drug discovery, Evotec and Bristol Myers Squibb Advance Neuroscience Collaboration with New Funding Milestone, Evotec SE, EVT8683, milestone payment, neurodegenerative diseases, neuroscience, neuroscience collaboration, neuroscience research, pharmaceutical innovation, preclinical research, strategic partnership, translational medicine
(IN BRIEF) Symrise has made a strategic equity investment in U.S.-based biotech firm Cellibre to drive innovation in sustainable biomanufacturing. The collaboration will accelerate the commercialization of natural flavor ingredients and cosmetic bioactives produced through precision fermentation. By combining Symrise’s … Read the full press release
Posted in Apparel, Fashion & Beauty, Chemicals, Food & Beverage, Germany, Marketing, Pharma & Biotech
Tagged Ben Chiarelli, biomanufacturing, biotechnology, biotechnology investment, Cellibre, Clean Beauty, corporate sustainability, cosmetic bioactives, environmental responsibility, fermentation-derived ingredients, food and beverage industry, global supply chain, Imke Meyer, natural flavors, nutraceuticals, Precision Fermentation, sustainable cosmetics, Sustainable Ingredients, sustainable innovation, Symrise, Symrise Partners with Cellibre to Accelerate Biotechnology Innovation in Natural Flavors and Cosmetic Actives, taste balancing
(IN BRIEF) Sanofi’s investigational therapy efdoralprin alfa met all primary and key secondary endpoints in the Phase 2 ElevAATe study for alpha-1 antitrypsin deficiency emphysema, demonstrating superior efficacy compared to standard plasma-derived therapy. The results highlight its potential as the … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged AATD emphysema, alpha-1 antitrypsin deficiency, biotechnology, Christopher Corsico, clinical research, David Geffen School of Medicine, efdoralprin alfa, ElevAATe OLE, ElevAATe study, FDA Fast Track, functional AAT, Igor Barjaktarevic, orphan drug designation, phase 2 trial, protein replacement therapy, pulmonary medicine, rare disease, recombinant therapy, respiratory health, respiratory innovation, Sanofi, Sanofi’s Efdoralprin Alfa Shows Superior Results in Phase 2 AATD Emphysema Trial, SAR447537, UCLA
(IN BRIEF) A new expert-led publication in the European Medical Journal, supported by Bayer, highlights the growing global burden of allergic rhinitis (hay fever) among children. Affecting 20% of children worldwide, the condition is linked to reduced academic performance, poor … Read the full press release
Posted in Education, Environment, Infrastructure & Utilities, News, Pharma & Biotech, Science, Society, Switzerland, Technology
Tagged academic performance, allergic rhinitis, allergy-friendly schools, antihistamines, ARIA guidelines, asthma prevention, Basel, Bayer, child wellbeing, children’s health, climate change, European Medical Journal, Experts Call for Urgent Action to Address the Growing Impact of Allergic Rhinitis on Children’s Health and Education, Experts Urge Global Action to Combat the Hidden Toll of Allergic Rhinitis on Children’s Education and Wellbeing, Gabriela Zuniga, global health, hay fever, indoor allergens, Lei Cheng, Mário Morais-Almeida, Michael Blaiss, non-sedating antihistamines, pediatric allergy, pollution, Ricardo Salazar, school environment, sleep disturbance, urbanization
(IN BRIEF) SCHOTT Pharma has launched the industry’s first 5.5 ml prefillable staked-needle glass syringe, expanding its syriQ BioPure® platform to support biologic therapies designed for home administration. The syringe integrates seamlessly with Ypsomed’s YpsoMate® 5.5 ml autoinjector and Datwyler’s … Read the full press release
Posted in Business, Germany, Healthcare, Industrial, News, Pharma & Biotech, Science, Technology
Tagged Andreas Reisse, autoinjector, biologic therapies, biopharmaceuticals, chronic disease treatment, CPHI Frankfurt, Datwyler, drug delivery, glass syringe, Healthcare Innovation, homecare, large-volume injector, medical technology, patient care, pharmaceutical innovation, SCHOTT Pharma, SCHOTT Pharma and Ypsomed drive innovation in large-volume injectable drug delivery with new 5.5 ml syringe, SCHOTT Pharma unveils 5.5 ml BioPure glass syringe to advance home-based biologic treatments, Subcutaneous Injection, syriQ BioPure, tungsten-free syringe, Ulrike Bauer, YpsoMate, Ypsomed
(IN BRIEF) The Phase III RAMPART trial has demonstrated that combining the immunotherapy drugs durvalumab and tremelimumab after surgery significantly improves disease-free survival in patients with early-stage renal cell carcinoma (RCC). Led by the Medical Research Council Clinical Trials Unit … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca UK Limited, cancer recurrence, clinical trial, Combination Therapy, disease-free survival, durvalumab, ESMO 2025, European Society for Medical Oncology, ICR, immunotherapy, kidney cancer, Medical Research Council Clinical Trials Unit, MRC CTU, oncology research, precision medicine, Professor Angela Meade, Professor James Larkin, RAMPART trial, RAMPART trial confirms combination immunotherapy reduces recurrence risk in kidney cancer after surgery, RCC, renal cell carcinoma, The Institute of Cancer Research and Royal Marsden report breakthrough results in renal cancer immunotherapy trial, The Institute of Cancer Research London, The Royal Marsden Cancer Charity, The Royal Marsden NHS Foundation Trust, tremelimumab, UCL, University College London
(IN BRIEF) Long-term data from the international monarchE trial has confirmed that patients with HR+ and HER2- node-positive high-risk early breast cancer achieve better survival outcomes when treated with the targeted therapy abemaciclib in combination with standard hormone therapy. Presented … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged abemaciclib, Annals of Oncology, clinical trial, early breast cancer, Eli Lilly and Company, ESMO 2025, European Society for Medical Oncology, HER2 negative, high-risk breast cancer, hormone therapy, HR-positive, ICR, Long-term monarchE study confirms abemaciclib improves survival for high-risk early breast cancer patients, Long-Term Survival, metastatic disease, monarchE trial, National Institute for Health and Care Research, New monarchE data shows first major advance in adjuvant breast cancer survival outcomes in two decades, NIHR, oncology research, Professor Stephen Johnston, targeted therapy, The Institute of Cancer Research London, The Royal Marsden Cancer Charity, The Royal Marsden NHS Foundation Trust
(IN BRIEF) In recognition of World Statistics Day 2025, The Institute of Cancer Research (ICR), London, is spotlighting the essential role of statisticians in advancing cancer research through reliable, transparent, and responsible data analysis. The event, themed “Quality statistics and … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged adaptive trial designs, artificial intelligence, biostatistics, cancer trials, clinical research, Clinical Trials and Statistics Unit, Covid-19 pandemic, CTSU, data transparency, Emily Alger, evidence-based decision making, ICR, ICR showcases how statistical science powers cancer research and clinical progress for World Statistics Day 2025, Machine Learning, oncology research, patient-reported outcomes, Professor Christina Yap, quality statistics, responsible research, statistical science, The Institute of Cancer Research celebrates the power of statistics in advancing cancer research ahead of World Statistics Day 2025, The Institute of Cancer Research London, University of Oxford, University of Warwick, World Statistics Day 2025
(IN BRIEF) A new global analysis by The Institute of Cancer Research (ICR), London, has found that cancer incidence is rising in both younger and older adults, disputing the idea that the global increase is limited to those under 50. … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Annals of Internal Medicine, bowel cancer, breast cancer, cancer incidence, Cancer Prevention, early-onset cancer, endometrial cancer, epidemiology, Global analysis from ICR challenges belief that cancer surge affects only younger adults, Global study, global trends, GLOBOCAN, IARC, ICR, International Agency for Research on Cancer, kidney cancer, leukaemia, Obesity, Older Adults, Professor Amy Berrington, Professor Kristian Helin, public health, screening, The Institute of Cancer Research London, The Institute of Cancer Research study finds cancer rates rising among both younger and older adults worldwide, thyroid cancer, World Health Organization, younger adults
(IN BRIEF) EDAP TMS SA has secured a €36 million credit facility from the European Investment Bank (EIB), supported by the European Commission’s InvestEU guarantee, to boost the global expansion of its Focal One® Robotic HIFU platform and fund new … Read the full press release
Posted in Banks, Financial, Healthcare, Investment, Luxembourg, News, Pharma & Biotech, Science, Technology
Tagged Ambroise Fayolle, biotechnology, credit facility, EDAP Strengthens Growth Strategy with EIB-Backed €36 Million Credit Facility for Non-Invasive Medical Technology Expansion, EDAP TMS, EIB, endometriosis, EU innovation support, European Investment Bank, European Investment Bank Backs EDAP TMS with €36 Million Credit Facility under InvestEU Program, Focal One, gynecology, Healthcare Innovation, high-intensity focused ultrasound, InvestEU, Lyon, medical technology, non-invasive therapy, prostate cancer, Robotic HIFU, Ryan Rhodes, SEC filing, urology
(IN BRIEF) EQT Foundation has invested €100,000 in Syngular Technology, a Hong Kong-based startup developing an AI- and AR-powered surgical guidance platform. The company’s system integrates extended reality and artificial intelligence to deliver real-time, spatially aware surgical support that enhances … Read the full press release
Posted in Artificial Intelligence (AI), Business, Healthcare, Industrial, Investment, Pharma & Biotech, Small Business, Sweden, Technology
Tagged AI, AR, artificial intelligence, augmented reality, Cilia Holmes Indahl, Digital Twin, EQT Foundation, EQT Foundation Backs Syngular Technology to Advance AI and AR Surgical Solutions in Hong Kong, EQT Impact Challenge, Extended Reality, healthcare technology, healthtech, Hong Kong, hospital systems, Louis Sze, medical imaging, Medical Innovation, precision medicine, surgery, surgical guidance, Syngular Technology, Syngular Technology Secures Investment from EQT Foundation to Scale Intelligent Surgical Guidance Platform, XR
(IN BRIEF) Roche reported groundbreaking phase III IMvigor011 results showing that Tecentriq (atezolizumab) significantly improved overall and disease-free survival in muscle-invasive bladder cancer using a ctDNA-guided treatment approach. Patients receiving Tecentriq experienced a 41% lower risk of death and a … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged adjuvant therapy, atezolizumab, bladder cancer, Cancer Immunotherapy, ctDNA, disease-free survival, ESMO Congress 2025, IMvigor011, Levi Garraway, molecular residual disease, MRD testing, muscle-invasive bladder cancer, Natera, oncology research, precision oncology, Roche, Roche Advances Personalized Oncology with Positive Phase III Tecentriq Results in ctDNA-Directed Bladder Cancer Treatment, Roche’s Tecentriq Shows 41% Survival Benefit in Landmark ctDNA-Guided Bladder Cancer Study, Signatera, survival benefit, TECENTRIQ, Thomas Powles
(IN BRIEF) Roche has received FDA approval for Gazyva/Gazyvaro (obinutuzumab) as a treatment for adult patients with active lupus nephritis, supported by data from the NOBILITY and REGENCY trials that showed significantly improved renal response compared with standard therapy. The … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged anti-CD20 monoclonal antibody, autoimmune disease, autoimmune therapy, biopharmaceuticals, CHMP, European Medicines Agency, FDA approval, Gazyva, Gazyva/Gazyvaro Approved by FDA as First Anti-CD20 Therapy to Achieve Complete Renal Response in Lupus Nephritis, Gazyvaro, kidney disease, Levi Garraway, Louise Vetter, Lupus Foundation of America, lupus nephritis, nephrology, NOBILITY trial, obinutuzumab, REGENCY trial, renal response, Roche, Roche Basel, Roche Strengthens Autoimmune Portfolio with FDA Approval of Gazyva/Gazyvaro for Lupus Nephritis Treatment, systemic lupus erythematosus
(IN BRIEF) Evotec SE has announced that Esperion Therapeutics has nominated an oral preclinical development candidate for primary sclerosing cholangitis (PSC), marking a major milestone in their collaboration. The PDC, developed through Evotec’s integrated small molecule discovery platform and Esperion’s … Read the full press release
Posted in Business, Germany, Government, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged ACLY biology, bile ducts, clinical development, collaboration, Cord Dohrmann, drug discovery, Esperion Therapeutics, Evotec Advances Collaboration with Esperion as New ACLY-Based Candidate Targets Primary Sclerosing Cholangitis, Evotec and Esperion Advance Novel Treatment Candidate for Primary Sclerosing Cholangitis, Evotec INDiGO, Evotec SE, fibrosis, Frankfurt Stock Exchange EVT, hepatology, IND-enabling platform, liver disease, milestone payment, NASDAQ ESPR, NASDAQ EVO, preclinical development candidate, primary sclerosing cholangitis, PSC, rare diseases
(IN BRIEF) GSK’s Shingrix vaccine has been approved by China’s NMPA for adults aged 18 and over who are immunocompromised or immunosuppressed, marking the first shingles vaccine available for this group in the country. Affecting about six million people annually … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged CHINA, China National Medical Products Administration, clinical studies, global health, GSK, GSK Expands Shingrix Approval in China to Include Immunocompromised Adults at Risk of Shingles, GSK Strengthens Vaccine Portfolio with Shingrix Approval for High-Risk Adult Populations in China, GSK Wins China Approval for Shingrix in Immunocompromised Adults Expanding Protection Against Shingles, Healthcare, herpes zoster, immunocompromised adults, immunodeficiency, immunosuppression, infectious diseases, NMPA, preventive medicine, public health, Recombinant Zoster Vaccine, RZV, Sanjay Gurunathan, Shingles, Shingrix, vaccine approval, Vaccine Innovation
(IN BRIEF) Researchers at the University of Bristol have developed a promising new gene therapy that could help prevent diabetic kidney disease in people with type 1 diabetes. The treatment uses a harmless virus to deliver the VEGF-C protein directly … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged albuminuria, Aldara Martin Alonso, American Diabetes Association, biomedical research, Bristol Medical School, Chronic kidney disease, diabetes complications, Diabetes UK, Diabetes UK and University of Bristol Study Finds Gene Therapy Could Halt Kidney Disease Progression, diabetic kidney disease, Faye Riley, gene therapy, glomerulus, kidney health, Molecular Therapy, Rebecca Foster, Translational Health Sciences, type 1 diabetes, University of Bristol, University of Bristol Researchers Pioneer New Gene-Based Treatment for Diabetic Kidney Damage, University of Bristol Unveils Gene Therapy Breakthrough to Prevent Kidney Disease in Type 1 Diabetes, VEGF-C
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?